Or an effective intranasal sars-cov-2 specific vaccines that provides good protection from infection/spread in the upper respiratory mucosa. This is to complement the strong protection against serious disease in the body serum/lower lungs that intramuscular vaccines give.
I have high hopes for India's now approved (positive phase 3 trials) adenovirus based one even if astrozenacca's rushed repackaging of theirs as intranasal failed.
I have high hopes for India's now approved (positive phase 3 trials) adenovirus based one even if astrozenacca's rushed repackaging of theirs as intranasal failed.